Biotech investors and industry observers are anxiously awaiting the Supreme Court's verdict over the patent surrounding Myriad Genetics' BRAC Analysis diagnostic, the same test that spurred Angelina Jolie to undergo her pre-emptive double mastectomy. However, that wasn't the only biotech patent decision the high court was ruling on this session.
In this video, health-care analyst David Williamson discusses the implications of Monsanto's win for investors in the agricultural and biotech industries.
Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.